|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 8
Zeitschriftenartikel
Berthold, F.; Faldum, A.; Ernst, A.; Boos, J.; Dilloo, D.; Eggert, A.; Fischer, M.; Fruehwald, M.; Henze, G.; Klingebiel, T.; Kratz, C.; Kremens, B.; Krug, B.; Leuschner, I; Schmidt, M.; Schmidt, R.; Schumacher-Kuckelkorn, R.; Schweinitz, D. von; Schilling, F. H.; Theissen, J.; Volland, R.; Hero, B. und Simon, T.
(2020):
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR.
In: Annals of Oncology, Bd. 31, Nr. 3: S. 422-429
Prassek, V. V.; Rothenberg-Thurley, M.; Sauerland, M. C.; Amler, S.; Görlich, D.; Herold, T.; Janke, H.; Schneider, S.; Subklewe, M.; Krug, U.; Faldum, A.; Berdel, W.; Wörmann, B.; Bräss, J.; Spiekermann, K.; Hiddemann, W. und Metzeler, K.
(2017):
AML patients aged >= 75 years enrolled into AMLCG trials: do genetic alterations impact clinical outcome in very old, intensively treated patients?
In: Oncology Research and Treatment, Bd. 40: S. 29
Prassek, V.; Rothenberg-Thurley, M.; Sauerland, M. C.; Amler, S.; Görlich, D.; Herold, T.; Janke, H.; Schneider, S.; Subklewe, M.; Krug, U.; Faldum, A.; Berdel, W. E.; Wörmann, B.; Braess, J.; Hiddemann, W.; Spiekermann, K. und Metzeler, K. H.
(2017):
AML patients aged >= 75 years enrolled into AMLCG trials: do genetic alterations impact clinical outcome in very old, intensively treated patients?
In: Haematologica, Bd. 102: S. 209-210
Prassek, V. V.; Rothenberg-Thurley, M.; Herold, T.; Amler, S.; Sauerland, M. C.; Goerlich, D.; Janke, H.; Schneider, S.; Subklewe, Marion; Krug, U.; Faldum, A.; Berdel, W. E.; Woermann, B.; Buechner, T.; Braess, J.; Hiddemann, W.; Spiekermann, K. und Metzeler, K. H.
(2017):
AML Patients Aged >= 75 Years Enrolled into AMLCG Trials: Do Gene Mutations Impact Clinical Outcome in Very Old, Intensively Treated Patients?
In: Annals of Hematology, Bd. 96:
S63-S63
Rothenberg-Thurley, M.; Amler, S.; Goerlich, D.; Sauerland, M. C.; Schneider, S.; Konstandin, N. P.; Batcha, A. M.; Ksienzyk, B.; Zellmeier, E.; Mansmann, Ulrich; Subklewe, Marion; Bohlander, S. K.; Faldum, A.; Hiddemann, W.; Spiekermann, K.; Braess, J. und Metzeler, Klaus H.
(2017):
Persistence of Driver Mutations during Complete Remission Associates with Shorter Survival and Contributes to the Inferior Outcomes of Elderly Patients with Acute Myeloid Leukemia.
In: Annals of Hematology, Bd. 96:
S31-S32
Büchner, T.; Krug, U. O.; Gale, R. Peter; Heinecke, A.; Sauerland, M. C.; Haferlach, C.; Schnittger, S.; Haferlach, T.; Müller-Tidow, C.; Stelljes, M.; Mesters, R. M.; Serve, H. L.; Braess, J.; Spiekermann, K.; Staib, P.; Grüneisen, A.; Reichle, A.; Balleisen, L.; Eimermacher, H.; Giagounidis, A.; Rasche, H.; Lengfelder, E.; Görlich, D.; Faldum, A.; Köpcke, W.; Hehlmann, R.; Wörmann, B. J.; Berdel, W. E. und Hiddemann, W.
(2016):
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.
In: Leukemia, Bd. 30, Nr. 8: S. 1781-1784
Rothenberg-Thurley, M.; Amler, S.; Goerlich, D.; Sauerland, M. C.; Schneider, S.; Konstandin, N. P.; Schaaf, S.; Batcha, A. M. Nazeer; Bräundl, K.; Ksienzyk, B.; Zellmeier, E.; Mansmann, Ulrich; Fiegl, M.; Subklewe, M.; Bohlander, S. K.; Faldum, A.; Hiddemann, W.; Spiekermann, K.; Braess, J. und Metzeler, K. H.
(2016):
Persistence of driver mutations during complete remission associates with shorter survival and contributes to the inferior outcomes of elderly patients with acute myeloid leukemia.
In: Haematologica, Bd. 101: S. 23
Rothenberg-Thurley, M.; Amler, S.; Görlich, D.; Sauerland, M. C.; Schneider, S.; Konstandin, N. P.; Schaaf, S.; Nazeer Batcha, A. M.; Bräundl, K.; Ksienzyk, B.; Zellmaier, E.; Mansmann, Ulrich; Fiegl, M.; Subklewe, M.; Bohlander, S. K.; Faldum, A.; Hiddemann, W.; Spiekermann, K.; Braess, J. und Metzeler, K. H.
(2016):
Persistence of driver mutations during complete remission associates with shorter survival and contributes to the inferior outcomes of elderly patients with acute myeloid leukemia.
In: Oncology Research and Treatment, Bd. 39: S. 110-111